| Mesothelioma |
1 |
1 |
| Biologic Therapy |
0 |
0.97 |
| Non-Small Cell Lung Cancer |
0 |
0.67 |
| Cancer |
0 |
0.61 |
| Lung Cancer |
0 |
0.58 |
| Chemotherapy |
0 |
0.51 |
| Small Cell Lung Cancer |
0 |
0.51 |
| Targeted Cancer Therapy |
0 |
0.48 |
| CAR-T |
0 |
0.36 |
| Radiation Therapy |
0 |
0.28 |
| Immunotherapy |
0 |
0.23 |
| Lung |
0 |
0.23 |
| T-Lymphocyte |
0 |
0.19 |
| Angiogenesis Inhibitors |
0 |
0.09 |
| Biomarker |
0 |
0.09 |
| Clinical Guidelines |
0 |
0.09 |
| Clinical Research |
0 |
0.09 |
| Food and Drug Administration (FDA) |
0 |
0.09 |
| Histology |
0 |
0.09 |
| Humanized Monoclonal Antibody |
0 |
0.09 |
| Prognosis |
0 |
0.09 |
| Surgery |
0 |
0.09 |
| Tumor |
0 |
0.09 |
| Antigens |
0 |
0.05 |
| Anxiety |
0 |
0.05 |
| Attending Physician |
0 |
0.05 |
| Epidemiology |
0 |
0.05 |
| Hematologic Malignancies |
0 |
0.05 |
| Investment |
0 |
0.05 |
| New York |
0 |
0.05 |
| Quality of Life |
0 |
0.05 |
| Radiation Pneumonitis |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Statistics |
0 |
0.05 |
| Texas |
0 |
0.05 |
| Thorax |
0 |
0.05 |
| Anxiety Disorder |
0 |
0.04 |
| Pneumonia |
0 |
0.04 |